BIOMARIN PHARMACEUTICAL INC Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- BIOMARIN PHARMACEUTICAL INC stock issued during period, value, new issues for the quarter ending 2016-12-31 was $0.00.
- BIOMARIN PHARMACEUTICAL INC stock issued during period, value, new issues for fiscal 2016 was $712.94M, a 19.74% decline from fiscal 2015.
- BIOMARIN PHARMACEUTICAL INC stock issued during period, value, new issues for fiscal 2015 was $888.26M, a 656.20% increase from fiscal 2014.
- BIOMARIN PHARMACEUTICAL INC stock issued during period, value, new issues for fiscal 2014 was $117.46M, a 17.61% increase from fiscal 2013.
- BIOMARIN PHARMACEUTICAL INC stock issued during period, value, new issues for fiscal 2013 was $99.88M, a 57.59% decline from fiscal 2012.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2016-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-28 | $712.94M 10-K · filed 2019-02-28 |
| 2015-12-31 | $888.26M 10-K · filed 2018-02-26 | |
| 2014-12-31 | $117.46M 10-K · filed 2017-02-27 | |
| 2013-12-31 | $99.88M 10-K · filed 2016-02-29 | |
| 2012-12-31 | $235.50M 10-K · filed 2015-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |